Multimodal Therapy of Recurrent Malignant Schwannoma
Authors:
O. Kalita 1; K. Cwiertka 2; D. Vrána 2; M. Vaverka 1; L. Tučková 3; M. Megová 4
Authors‘ workplace:
Neurochirurgická klinika LF UP a FN Olomouc
1; Onkologická klinika LF UP a FN Olomouc
2; Laboratoř molekulární patologie, Oddělení patologie, Ústav molekulární a translační medicíny, LF UP a FN Olomouc
3; Ústav molekulární a translační medicíny, LF UP v Olomouci
4
Published in:
Klin Onkol 2016; 29(5): 364-368
Category:
Case Reports
doi:
https://doi.org/10.14735/amko2016364
Overview
Background:
Malignant peripheral nerve sheath tumor schwannoma (MPNST), also known as malignant schwannoma, is a very rare tumor accounting for only 2% of all sarcomas. The prognosis is relatively poor, with a 5-year survival rate of 46–69%. The treatment of MPNST has not been standardized yet. Mainstay treatment is radical resection. Oncological adjuvant or neoadjuvant treatment has equivocal indications with unclear effects.
Case:
The case report presents a 55-year-old patient who showed resistance in the medial-ventral area of the left lower limb. An MRI scan showed a tumor adjacent to the femoral nerve. Tumor extirpation was performed. Histology revealed malignant schwannoma (MPNST) and the resection was assessed as R0. Postoperative whole-body PET/CT revealed no viable tumor tissue. The patient was regularly followed-up. On a follow-up MRI scan, performed 53 months after initial surgery, tumor recurrence was detected in the left thigh. Extirpation of the recurrent tumor was performed. Histology confirmed MPNST and the resection radicality was assessed as R2. Postoperative PET/CT revealed tumor residues. Therefore, 58 months after the initial surgery, another operation of the residual tumor was performed with R0 resection. Three applicators for interstitial brachytherapy were placed in the resection cavity. Following the operation, radiotherapy with an interstitial brachytherapy boost of 18 Gy followed by external fractionated radiotherapy of 50 Gy were administered. The latest MRI scan, performed 66 months after the diagnosis of MPNST, showed no tumor tissue. The patient had no neurological deficit.
Conclusion:
The mainstay of treatment for MPNST is radical en bloc resection. The use of subsequent oncological therapy depends on the radicality of the resection. In our case, because of the good radicality of the initial surgery, adjuvant oncological therapy was postponed. As part of recurrence management, we again attempted to achieve the most radical resection possible and then apply adjuvant radiotherapy. In MPNST, as in all soft tissue sarcomas, high doses are chosen because of potential radioresistance. Given the confined nature of the disease, we chose this locally intensified therapeutic strategy, which resulted in this case in disease remission. Due to the low incidence of MPNST, it is not possible to test the efficacies of individual oncologic therapeutic procedures in larger patient cohorts.
Key words:
malignant schwannoma – soft tissue sarcoma – multimodal therapy
The authors declare they have no potential confl icts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.
Submitted:
13. 3. 2016
Accepted:
25. 4. 2016
Sources
1. Ng VY, Scharschmidt TJ, Mayerson JL et al. Incidence and survival in sarcoma in the United States: a focus on musculoskeletal lesions. Anticancer Res 2013; 33 (6): 2597–2604.
2. Žaloudík J, Taláč R, Vagunda V et al. Sarkomy měkkých tkání – přehled novějších diagnostických a léčebných postupů. Klin Onkol 2000; 13 (5): 141–150.
3. Ducatman BS, Scheithauer BW, Piepgras DG et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986; 57 (10): 2006–2021.
4. Valentin T, Le Cesne A, Ray-Coquard I et al. Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer 2016; 56 (3): 77–84. doi: 10.1016/j.ejca.2015.12.015.
5. Zou C, Smith KD, Liu J et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg 2009; 249 (6): 1014–1022. doi: 10.1097/SLA.0b013e3181a77 e9a.
6. LaFemina J, Qin LX, Moraco NH et al. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors. Ann Surg Oncol 2013; 20 (1): 66–72. doi: 10.1245/s10434-012-2573-2.
7. Stucky CC, Johnson KN, Gray RJ et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo clinic experience. Ann Surg Oncol 2012; 19 (3): 878–885. doi: 10.1245/s10434-011-1978-7.
8. Anghileri M, Miceli R, Fiore M et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer 2006; 107 (5): 1065–1074.
9. Longhi A, Errani C, Magagnoli G et al. High grade malignant peripheral nerve sheath tumors: outcome of 62 patients with localized disease and review of the literature. J Chemother 2010; 22 (6): 413–418.
10. Porter DE, Prasad V, Foster L et al. Survival in malignant peripheral nerve sheath tumors: a comparison between sporadic and neurofibromatosis type 1-associated tumors. Sarcoma 2009; 2009: ID 756395. doi: 10.1155/2009/756395.
11. Kolberg M, Høland M, Agesen TH et al. Survival meta-analyses for > 1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol 2013; 15 (2): 135–147. doi: 10.1093/ neuonc/nos287.
12. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 (Suppl 3): iii102–iii112. doi: 10.1093/annonc/mdu254.
13. Harbitz F. Multiple neurofibromatosis (von Recklinghausen’s disease). Arch Int Med 1909; 3 (1): 32–65. doi: 10.1001/archinte.1909.00050120047003.
14. Sordillo PP, Helson L, Hajdu SI et al. Malignant schwannomaeclinical characteristics, survival, and response to therapy. Cancer 1981; 47 (10): 2503–2509.
15. Grobmyer SR, Reith JD, Shahlaee A et al. Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations. J Surg Oncol 2008; 97 (4): 340–349. doi: 10.1002/jso.20971.
16. Gupta G, Mammis A, Maniker A. Malignant peripheral nerve sheath tumors. Neurosurg Clin N Am 2008; 19 (4): 533–543. doi: 10.1016/j.nec.2008.07.004.
17. Widemann BC. Current status of sporadic and neurofibromatosis type 1 – associated malignant peripheral nerve sheath tumors. Curr Oncol Rep 2009; 11 (4): 322–328.
18. Beneš V III, Kramář F, Hrabal P et al. Maligní tumor z pochvy periferního nervu – dvě kazuistiky. Cesk Slov Neurol N 2009; 72/105 (2): 163–167.
19. Kadaňka Z Jr, Hanák J, Gál B. Maligní tumor z pochvy periferního nervu v oblasti cervikálního plexu – kazuistika. Cesk Slov Neurol N 2013; 76/109 (6): 751–755.
20. Watson MA, Perry A, Tihan T et al. Gene expression profiling reveals unique molecular subtypes of neurofibromatosis type I – associated and sporadic malignant peripheral nerve sheath tumors. Brain Pathol 2004; 14 (3): 297–303.
21. Henderson SR, Guiliano D, Presneau N et al. A molecular map of mesenchymal tumors. Genome Biol 2005; 6 (9): R76.
22. Karube K, Nabeshima K, Ishiguro M et al. cDNA microarray analysis of cancer associated gene expression profiles in malignant peripheral nerve sheath tumours. J Clin Pathol 2006; 59 (2): 160–165.
23. Miller SJ, Rangwala F, Williams J et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res 2006; 66 (5): 2584–2591.
24. Francis P, Namløs HM, Muller C et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 2007; 8: 73.
25. Lévy P, Ripoche H, Laurendeau I et al. Microarray-based identification of tenascin C and tenascin XB, genes possibly involved in tumorigenesis associated with neurofibromatosis type 1. Clin Cancer Res 2007; 13 (2 Pt 1): 398–407.
26. Agesen TH, Flørenes VA, Molenaar WM et al. Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1 – related malignant peripheral nerve sheath tumors. J Neuropathol Exp Neurol 2005; 64 (1): 74–81.
27. Cichowski K, Shih TS, Schmitt E et al. Mouse models of tumor development in neurofibromatosis type 1. Science 1999; 286 (5447): 2172–2176.
28. Vogel KS, Klesse LJ, Velasco-Miguel S et al. Mouse tumor model for neurofibromatosis type 1. Science 1999; 286 (5447): 2176–2179.
29. Zöller M, Rembeck B, Akesson HO et al. Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Goteborg, Sweden. Acta Derm Venereol 1995; 75 (2): 136–140.
30. Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis 1: an analysis using U. S. death certificates. Am J Hum Genet 2001; 68 (5): 1110–1118.
31. Evans DG, O’Hara C, Wilding A et al. Mortality in neurofibromatosis 1: in NorthWest England: an assessment of actuarial survival in a region of the UK since 1989. Eur J Hum Genet 2011; 19 (11): 1187–1191. doi: 10.1038/ejhg.2011.113.
32. Masocco M, Kodra Y, Vichi M et al. Mortality associated with neurofibromatosis type 1: a study based on Italian death certificates (1995–2006). Orphanet J Rare Dis 2011; 6: 11. doi: 10.1186/1750-1172-6-11.
33. Coindre JM. Grading of soft tissue sarcomas: review and update. Arch Pathol Lab Med 2006; 130 (10): 1448–1453.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2016 Issue 5
Most read in this issue
- The Impact of High Protein Nutritional Support on Clinical Outcomes and Treatment Costs of Patients with Colorectal Cancer
- Treatment of Relapsed and Refractory Hodgkin Lymphoma – Recommendations of the Czech Hodgkin Lymphoma Study Group
- Malignant Mesothelioma of the Tunica Vaginalis Testis. A Clinicopathologic Analysis of Two Cases with a Review of the Literature
- Multimodal Therapy of Recurrent Malignant Schwannoma